Table 1.
Relationships between cardiovascular events and activity of drugs used in NSCLC.
| Cardiac Toxic Effects | Vascular Toxic Effects | ||||||
|---|---|---|---|---|---|---|---|
| Heart Failure/Cardiac Dysfunction | Atrial Fibrillation/ECG Changes | Myocarditis/Pericarditis | Venous Thromboembolism | Acute Coronary Events | Hypertension | ||
| Cytostatic agents | Cisplatin | ↑ in elderly | ↑ | ↑↑↑ | ↑↑↑ | ↑ as late effect | |
| Gemcitabine | ↑↑↑ | ↑↑↑ | |||||
| Vinorelbine | ↑ combined with cisplatin | ↑↑↑ | |||||
| Taxanes | ↑↑↑ | ↑↑↑ | |||||
| Pemetrexed | ↑ in combined chemotherapy | ||||||
| EGFR inhibitors | Erlotinib | ↑↑↑ | ↑↑↑ | ||||
| Gefitinib | ↑ | ||||||
| Afatinib | ↑ | ||||||
| Osimertinib | ↑↑↑ | ↑↑↑ | |||||
| ALK inhibitors | Crizotinib | ↑↑↑ | |||||
| Ceritinib | ↑↑↑ | ↑ | |||||
| Alectinib | ↑ | ||||||
| Brigatinib | ↑ | ||||||
| VEGF inhibitors | Bevacizumab | ↑ | ↑↑↑ | ↑↑↑ | ↑↑↑ | ||
| Nintedanib | ↑↑↑ | ↑↑↑ | |||||
| Immune checkpoint inhibitors | Pembrolizumab | ↑ differential diagnosis of reasons is needed | ↑↑↑ | ↑↑↑ | |||
| Nivolumab | |||||||
| Atezolizumab | |||||||
| Durvalumab | |||||||
Legend: ↑↑↑-clearly confirmed effect; ↑-observed effect in selected patients.